Achilladelis, B. & Antonakis, N. 2001. The dynamics of technological innovation: the case of the pharmaceutical industry. Research Policy, 30(4), pp. 535-588.
Adler, P.S. & Shenbar, A. 1990. Adapting your technological base: the organizational challenge. Sloan Management Review, 32(1), pp.25-37.
Aerts, K. & Schmidt, T. 2008. Two for the price of one?: Additionality effects of R&D subsidies: A comparison between Flanders and Germany. Research policy, 37(5), pp. 806-822.
Afcha Chávez, S.M. 2011. Behavioural additionality in the context of regional innovation policy in Spain. Innovation, 13(1), pp. 95-110.
Ambrosini, V. & Bowman, C. 2009. What are dynamic capabilities and are they a useful construct in strategic management? International Journal of Management Reviews, 11(1), pp.29-49.
Arora, A., Gambardella, A., Magazzini, L. & Pammolli, F. 2009. A breath of fresh air? Firm type, scale, scope, and selection effects in drug development. Management Science, 55(10), pp. 1638-1653.
Arrow, K. 1962. Economic welfare and the allocation of resources for invention. The rate and direction of inventive activity: Economic and social factors. Princeton University Press. pp. 609-626.
Ashford, N.A. & Heaton, G.R. 1983. Regulation and technological innovation in the chemical industry. Law and Contemporary Problems, 46(3), pp. 109-157.
Autio, E., Kanninen, S. & Gustafsson, R. 2008. First-and second-order additionality and learning outcomes in collaborative R&D programs. Research Policy, 37(1), pp. 59-76.
Barney, J. & Felin, T. 2013. What are microfoundations? The Academy of Management Perspectives, 27(2), pp. 138-155.
Barouni, M., Ghaderi, H. & Banouei, A. 2012. Pharmaceutical Industry and Trade Liberalization Using Computable General Equilibrium Model. Iranian Journal of Public Health, 41(12), pp. 66.
Basmenji, K. 2004. Pharmaceuticals in Iran: An Overview. Arch Iranian Med, 7(2), pp. 158-164.
Biernacki, P. & Waldorf, D. 1981. Snowball sampling: Problems and techniques of chain referral sampling. Sociological Methods & Research, 10(2), pp. 141-163.
Blind, K. 2010. The Use of the Regulatory Framework for Innovation Policy. In R. E. Smits, S. Kuhlmann & P. Shapira eds. The theory and practice of innovation policy: An international research handbook. Edward Elgar.
Blind, K., Buhrelen, B., Menrad, K., Hafner, S., Walz, R. & Kotz, C., 2004. New Products and Services: Analysis of Regulations Shaping New Markets: Study Funded by the European Commission, DG Enterprise/Innovation Policy Unit, in the Framework of the Innovation/SMEs Programme, Part of the Fifth Research Framework Programme.
Blume-Kohout, M.E. & Sood, N. 2013. Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development. Journal of Public Economics, Volume (97), pp. 327-336.
Boeing, P. 2014. China’s R&D Subsidies-Allocation and Effectiveness. ZEW-Centre for European Economic Research Discussion Paper(14-103).
Börjesson, S., Elmquist, M. & Hooge, S. 2014. The challenges of innovation capability building: Learning from longitudinal studies of innovation efforts at Renault and Volvo Cars. Journal of Engineering and Technology Management, Volume (31), pp. 120-140.
Borrás, S. & Edquist, C. 2013. Competence Building: A Systemic Approach to Innovation Policy. Lund University, CIRCLE-Center for Innovation, Research and Competences in the Learning Economy.
Bowman, C. & Ambrosini, V. 2003. How the resource-based and the dynamic capability views of the firm inform corporate-level strategy. British Journal of Management,14(4), pp. 289-303.
Bruni, D.S. & Verona, G. 2009. Dynamic marketing capabilities in Science-based firms: An exploratory investigation of the pharmaceutical industry. British Journal of Management, 20(1), pp. 101-117.
Buisseret, T.J., Cameron, H.M. & Georghiou, L. 1995. What difference does it make? Additionality in the public support of R&D in large firms. International Journal of Technology Management,10(4), pp. 587-600.
Busom, I., Corchuelo, B. & Martínez-Ros, E. 2014. Tax incentives or subsidies for business R&D? Small Business Economics, 43(3), pp. 571-596.
Chen, H.-h. 2003. Comparative Analysis and Benchmarking: Corporate Strategy Analysis of Four International Pharmaceutical Companies: Universal-Publishers.
Cheraghali, A., Nikfar, S., Behmanesh, Y., Rahimi, V., Habibipour, F., Tirdad, R., Asadi, A. & Bahrami, A.,. 2004. Evaluation of availability, accessibility and prescribing pattern of medicines in the Islamic Republic of Iran.
Cheraghali, A.M. 2006. Iran pharmaceutical market. Iranian Journal of Pharmaceutical Research, Volume(1), pp.1-7.
Choi, J.Y., Lee, J.H. & Sohn, S.Y. 2009. Impact analysis for national R&D funding in science and technology using quantification method II. Research Policy, 38(10), pp. 1534-1544.
Christensen, J.F. 1995. Asset profiles for technological innovation. Research Policy, 24(5), pp.727-745.
Clarysse, B., Wright, M. & Mustar, P. 2009. Behavioural additionality of R&D subsidies: A learning perspective. Research policy, 38(10), pp. 1517-1533.
Cohen, W.M. & Levinthal, D.A. 1990. Absorptive capacity: a new perspective on learning and innovation. Administrative Science Quarterly, 35(1), pp. 128-152.
Crafts, N. 2006. Regulation and productivity performance. Oxford Review of Economic Policy, 22(2), pp. 186-202.
Creswell, J.W. & Clark, V.L.P. 2007. Designing and conducting mixed methods research.
Czarnitzki, D., Ebersberger, B. & Fier, A. 2007. The relationship between R&D collaboration, subsidies and R&D performance: empirical evidence from Finland and Germany. Journal of Applied Econometrics, 22(7), pp. 1347-1366.
Czarnitzki, D. & Licht, G. 2006. Additionality of public R&D grants in a transition economy. Economics of Transition, 14(1), pp. 101-131.
Dai, X. & Cheng, L. 2015. The effect of public subsidies on corporate R&D investment: An application of the generalized propensity score. Technological Forecasting and Social Change, Volume (90), pp. 410-419.
Davari, M., Walley, T. & Haycox, A. 2011. Pharmaceutical Policy and Market in Iran: Past Experiences and Future Challenges. Journal of Pharmaceutical Health Services Research, 2(1), pp. 47-52.
Davenport, S., Grimes, C. & Davies, J. 1998. Research collaboration and behavioural additionality: a New Zealand case study. Technology Analysis & Strategic Management, 10(1), pp. 55-68.
Davit, B.M. et al. 2009. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Annals of Pharmacotherapy, 43(10), pp. 1583-1597.
DiMasi, J.A., Hansen, R.W., Grabowski, H.G. & Lasagna, L. 1991. Cost of innovation in the pharmaceutical industry. Journal of Health Economics, 10(2), pp.107-142.
Dinarvand, R. 2009. New national drug policy in Iran leading to expanded pharmaceutical market and extended access of public to medicines. Iranian J Publ Health, 38(1), pp. 158-161.
Dixon, S., Meyer, K. & Day, M. 2014. Building dynamic capabilities of adaptation and innovation: a study of micro-foundations in a transition economy. Long Range Planning, 47(4), pp. 186-205.
Dolfsma, W. & Seo, D. 2013. Government Policy and Technological Innovation—A Suggested Typology. Technovation, 33(6), pp. 173-179.
Dubois, P., de Mouzon, O., Scott‐Morton, F. & Seabright, P. 2015. Market size and pharmaceutical innovation. The RAND Journal of Economics, 46(4), pp. 844-871.
Duguet, E. 2003. Are R&D subsidies a substitute or a complement to privately funded R&D? Evidence from France using propensity score methods for non-experimental data. Evidence from France using Propensity Score Methods for Non-Experimental Data (July 2003). University of Paris I Cahier de la MSE EUREQua Working Paper(2003.75).
Eden, C. 2004. Analyzing cognitive maps to help structure issues or problems. European Journal of Operational Research, 159(3), pp. 673-686.
Edler, J. & Georghiou, L. 2007. Public Procurement and Innovation—Resurrecting the Demand Side. Research Policy, 36(7), pp. 949-963.
Eger, S. & Mahlich, J.C. 2014. Pharmaceutical regulation in Europe and its impact on corporate R&D. Health Economics Review, 4(1).
Eisenhardt, K.M. & Martin, J.A. 2000. Dynamic capabilities: what are they? Strategic Management Journal, 21(10-11), pp. 1105-1121.
Elsenhardt, K.M. & Martin, J.A. 2000. Dynamic capabilities: What are they. Strategic Management Journal , 21(1), pp. 1105-1121.
Falk, R. 2007. Measuring the effects of public support schemes on firms’ innovation activities: Survey evidence from Austria. Research Policy, 36(5), pp.665-679.
Felin, T., Foss, N.J., Heimeriks, K.H. & Madsen, T.L. 2012. Microfoundations of routines and capabilities: Individuals, processes, and structure. Journal of Management Studies, 49(8), pp. 1351-1374.
Francis, J.G. 1993. The politics of regulation: a comparative perspective: Cambridge Univ Press.
Galunic, D.C. & Eisenhardt, K.M. 2001. Architectural innovation and modular corporate forms. Academy of Management Journal, 44(6), pp. 1229-1249.
Gao, C. 2014. The effect of American industry deregulation on firm innovation behaviors: a difference in differences approach. University of Delaware.
Georghiou, L. 1994. Impact of the framework programme on European industry: European Commission, Directorate General Telecommunications, Information Market and Exploitation of Research.
Georghiou, L. 2002. Impact and additionality of innovation policy. IWT Studies, Volume (40), pp.57-64.
Georghiou, L. 2006. Effective innovation policies for Europe—The missing demand-side. Economic Council of Finland.
Georghiou, L. & Clarysse, B. 2006. Introduction and synthesis. In OECD ed. Government R&D Funding and Company Behaviour: Measuring Behavioural Additionality. Paris, Organisation for Economic Co-operation and Development. pp. 9-38.
Georghiou, L. & Office., C. 1993. The impact of European Community policies for research and technological development upon science and technology in the United Kingdom: a report prepared for DGXII of the Commission of the European Communities and the UK Office of Science & Technology.
Giaccotto, C., Santerre, R. & Vernon, J. 2005. Drug Prices And R&D Investment Behavior In The Pharmaceutical Industry. The Journal Of Law & Economics, 48(1), pp. 195-214.
Gök, A. 2010. An evolutionary approach to innovation policy evaluation: Behavioural additionality and organisational routines. Manchester Business School.
Golec, J. & Vernon, J.A. 2010. Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms. Pharmacoeconomics, 28(8), pp. 615-628.
González, X. & Pazó, C. 2008. Do Public Subsidies Stimulate Private R&D Spending? Research Policy, 37(3), pp. 371-389.
Görg, H. & Strobl, E. 2007. The effect of R&D subsidies on private R&D. Economica, 74(294), pp. 215-234.
Gray, S.A., Gray, S., Cox, L.J. & Henly-Shepard, S. 2013. Mental modeler: a fuzzy-logic cognitive mapping modeling tool for adaptive environmental management. System Sciences (HICSS), 2013 46th Hawaii International Conference on, IEEE.
Guan, J. & Ma, N. 2003. Innovative capability and export performance of Chinese firms. Technovation, 23(9), pp. 737-747.
Guan, J. & Yam, R.C. 2015. Effects of government financial incentives on firms’ innovation performance in China: Evidences from Beijing in the 1990s. Research Policy, 44(1), pp. 273-282.
Haas, J.S., Phillips, K.A., Gerstenberger, E.P. & Seger, A.C. 2005. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997–2000. Annals of Internal Medicine, 142(11), pp. 891-897.
Hassali, M.A. et al. 2009. Consumers’ views on generic medicines: a review of the literature. International Journal of Pharmacy Practice, 17(2), pp. 79-88.
Helfat, C. & Peteraf, M. 2009. Understanding dynamic capabilities: progress along a developmental path. Strategic Organization, 7(1), pp. 91.
Helfat, C.E. et al. 2007. Dynamic capabilities: Understanding strategic change in organizations: John Wiley & Sons.
Helfat, C.E. & Peteraf, M.A. 2015. Managerial cognitive capabilities and the microfoundations of dynamic capabilities. Strategic Management Journal, 36(6), pp. 831-850.
Henly-Shepard, S., Gray, S.A. & Cox, L.J. 2015. The use of participatory modeling to promote social learning and facilitate community disaster planning. Environmental Science & Policy, Volume (45), pp. 109-122.
Heshmati, A. & Loof, H. 2005. The impact of public funds on private R&D investment: New evidence from a firm level innovation study.
Hotho, J.J., Becker-Ritterspach, F. & Saka-Helmhout, A. 2012. Enriching absorptive capacity through social interaction. British Journal of Management, 23(3), pp. 383-401.
Hsu, F.-M., Horng, D.-J. & Hsueh, C.-C. 2009. The effect of government-sponsored R&D programmes on additionality in recipient firms in Taiwan. Technovation, 29(3), pp. 204-217.
Huff, A.S. 1990. Mapping strategic thought: John Wiley & Sons.
Hussinger, K. 2008. R&D and subsidies at the firm level: An application of parametric and semiparametric two-step selection models. Journal of Applied Econometrics, 23(6), pp. 729-747.
Hyvärinen, J. & Rautiainen, A.-M. 2007. Measuring additionality and systemic impacts of public research and development funding—the case of TEKES, Finland. Research Evaluation, 16(3), pp. 205-215.
Kale, D. & Little, S. 2007. From imitation to innovation: The evolution of R&D capabilities and learning processes in the Indian pharmaceutical industry. Technology Analysis & Strategic Management, 19(5), pp. 589-609.
Katz, A. 2007. Pharmaceutical lemons: innovation and regulation in the drug industry. Michigan Telecommunications and Technology Law Review, 14(1), pp. 1-41.
Kebriaeezadeh, A. et al. 2013. Trend analysis of the pharmaceutical market in Iran; 1997–2010; policy implications for developing countries. DARU journal of pharmaceutical Sciences, 21(1), pp. 52.
Kelly, G. 1955. Personal construct psychology. New York: Norton.
Kemp, R. & Pontoglio, S. 2011. The innovation effects of environmental policy instruments-A typical case of the blind men and the elephant? Ecological Economics, Volume (72), pp. 28-36.
Knockaert, M., Spithoven, A. & Clarysse, B. 2014. The impact of technology intermediaries on firm cognitive capacity additionality. Technological Forecasting and Social Change, Volume (81), pp. 376-387.
Kobayashi, Y. 2014. Effect of R&D tax credits for SMEs in Japan: A Microeconometric Analysis Focused on Liquidity Constraints. Small Business Economics, 42(2), pp. 311-327.
Koch, T. 2006. Establishing rigour in qualitative research: the decision trail. Journal of Advanced Nursing, 53(1), pp. 91-100.
Koenig, P. & MacGarvie, M. 2011. Regulatory policy and the location of bio-pharmaceutical foreign direct investment in Europe. Journal of Health Economics, 30(5), pp. 950-965.
Lach, S. 2002. Do R&D subsidies stimulate or displace private R&D? Evidence from Israel. The Journal of Industrial Economics, 50(4), pp. 369-390.
Langfield-Smith, K. & Wirth, A. 1992. Measuring differences between cognitive maps. Journal of the Operational Research Society, 43(12), pp.1135-1150.
Lerner, J. 2000. The government as venture capitalist: the long-run impact of the SBIR program. The Journal of Private Equity, 3(2), pp. 55-78.
Lööf, H. & Heshmati, A. 2005. The impact of public funds on private R&D investment: New evidence from a firm level innovation study. MTT Discussion Papers, Volume (3), pp. 1-26.
Luukkonen, T. 1998. The difficulties in assessing the impact of EU framework programmes. Research Policy, 27(6), pp. 599-610.
Mahoney, R. 2007. Building Product Innovation Capability in Health. In A. Krattiger et al. eds. Intellectual property management in health and agricultural innovation: a handbook of best practices. UK, Oxford.
Majone, G. 1996: Regulating Europe. London: Routledge.
Markoczy, L. & Goldberg, J. 1995. A method for eliciting and comparing causal maps. Journal of Management, 21(2), pp. 305-333.
Metcalfe, J.S., Georghiou, L., Cunningham, P. & Cameron, H.M. 1992. Evaluation of the impact of European Community research programmes upon the competitiveness of European industry-Concepts and approaches. EUR 14198 EN. Research evaluation. Science and Technology Policy Series.
Montibeller, G. & Belton, V. 2006. Causal maps and the evaluation of decision options -a review. Journal of the Operational Research Society, 57(7), pp. 779-791.
Nadkarni, S. & Nah, F.F.-H. 2003. Aggregated causal maps: An approach to elicit and aggregate the knowledge of multiple experts. Communications of the Association for Information Systems, 12(1).
Nelson, R.R. & Winter, S. 1982. An evolutionary theory of economic change. Cambridge: Belknap.
Niosi, J. 2002. National systems of innovations are “x-efficient”(and x-effective): Why some are slow learners. Research Policy, 31(2), pp. 291-302.
O’Connor, G.C. 2008. Major innovation as a dynamic capability: A systems approach. Journal of Product Innovation Management, 25(4), pp. 313-330.
Onishi, K. & Nagata, A. 2010. Does Tax Credit for R&D Induce Additional R&D Investment?: Analysis on the effects of gross R&D credit in Japan. Journal of Science Policy and Research Management, Volume (24), pp. 400-412.
Pammolli, F., Magazzini, L. & Riccaboni, M. 2011. The productivity crisis in pharmaceutical R&D. Nature reviews. Drug discovery, 10(6).
Paraskevopoulou, E. 2012. Non-technological regulatory effects: Implications for innovation and innovation policy. Research Policy, 41(6), pp. 1058-1071.
Porter 1991. America’s green strategy. Scientific American, 264(4).
Porter, M. & Van der Linde, C. 1995. Toward a new conception of the environment-competitiveness relationship. The Journal of Economic Perspectives, 9(4), pp. 97-118.
Radas, S., Anić, I.-D., Tafro, A. & Wagner, V., 2015. The effects of public support schemes on small and medium enterprises. Technovation, Volume (38), pp. 15-30.
Ramos Perez, C. 2016. Designing a behavioural additionality evaluation methodology for the Knowledge Transfer Partnerships Scheme employing case-based methods and theory-based evaluation approaches. University of Manchester.
Rasekh, H.R., Mehralian, G. & Vatankhah-Mohammadabadi, A.A. 2012. Situation analysis of R & D activities: an empirical study in Iranian pharmaceutical companies. Iranian Journal of Pharmaceutical Research, 1(4), pp. 1013-1025.
Ratanawijitrasin, S. 2007. Drug Regulation and Incentives for Innovation: The Case of ASEAN. WHO. Available at: www. who. int/intellectualproperty/studies/Drugregulationincentives. pdf.
Reinkowski, J., Mitze, T., Alecke, B. & Untiedt, G. 2010. R&D Subsidies and Private Sector Innovativeness: New Empirical Evidence for East German Firms.
Riege, A.M. 2003. Validity and reliability tests in case study research: a literature review with “hands-on” applications for each research phase. Qualitative Market Research: An International Journal, 6(2), pp. 75-86.
Rodhain, F. 1999. Tacit to explicit: transforming knowledge through cognitive mapping—an experiment. Proceedings of the 1999 ACM SIGCPR conference on Computer personnel research, ACM.
Assessment of the public tools used to promote R&D investment in Spanish SMEs. Small Business Economics, 43(4), pp. 959-976.
Romero-Jordán, D., Delgado-Rodríguez, M.J., Álvarez-Ayuso, I. & de Lucas-Santos, S. 2014. Assessment of the public tools used to promote R&D investment in Spanish SMEs. Small Business Economics, 43(4), pp. 959-976.
Santerre, C.G.R.E. & Vernon, J.A. 2004. Drug Prices and R&D Investment Behavior in the Pharmaceutical Industry.
Seyedifar, M. et al. 2015. An evaluation of policies and procedures of successful pharmaceutical exporters and the comparison of Iranian counterpart policy. Journal of Pharmacoeconomics and Pharmaceutical Management, 1(3/4), pp. 39-44.
Shabaninejad, H. et al. 2014. Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market. DARU journal of pharmaceutical Sciences, 22(1), pp. 35.
Smith, K. 2000. Innovation as a systemic phenomenon: rethinking the role of policy. Enterprise and innovation management studies, 1(1), pp. 73-102.
Soete, L. et al. 2002. Benchmarking National Research Policies: The Impact of RTD on Competitiveness and Employ ment (IRCE). Strata-ETAN Expert Working Group, European Commission DG Research, Brussels.
Stewart, L.A. 2010. The Impact of Regulation on Innovation in the United States: A Cross-Industry Literature Review. USA, Information Technology & Innovation Foundation.
Strauss, K., Lepoutre, J. & Wood, G. 2017. Fifty shades of green: How microfoundations of sustainability dynamic capabilities vary across organizational contexts. Journal of Organizational Behavior, 38(9).
Teece, D. & Pisano, G. 1994. The dynamic capabilities of firms: an introduction. Industrial and Corporate change, 3(3), pp. 537-556.
Teece, D.J. 2007. Explicating dynamic capabilities: the nature and microfoundations of (sustainable) enterprise performance. Strategic Management Journal, 28(13), pp. 1319-1350.
Teece, D.J. 2012. Dynamic capabilities: Routines versus entrepreneurial action. Journal of Management Studies, 49(8), pp.1395-1401.
Teece, D.J. 2017. Towards a capability theory of (innovating) firms: implications for management and policy. Cambridge Journal of Economics, 41(3), pp. 693-720.
Teece, D.J., Pisano, G. & Shuen, A. 1997. Dynamic capabilities and strategic management. Strategic Management Journal, Volume(18), pp. 509-533.
Tran, T.A. & Daim, T. 2008. A taxonomic review of methods and tools applied in technology assessment. Technological Forecasting and Social Change, 75(9), pp. 1396-1405.
Van Den Ende, J. et al. 1998. Traditional and modern technology assessment: toward a toolkit. Technological Forecasting and Social Change, 58(1), pp. 5-21.
Vernon, J.A. 2005. Examining the link between price regulation and pharmaceutical R&D investment. Health Economics, 14(1), pp. 1-16.
Wallsten, S.J. 2000. The effects of government-industry R&D programs on private R&D: the case of the Small Business Innovation Research program. The RAND Journal of Economics, 31(1), pp.82-100.
Wang, C.L. & Ahmed, P.K. 2007. Dynamic capabilities: A review and research agenda. International Journal of Management Reviews, 9(1), pp. 31-51.
Weber, K.M. & Rohracher, H. 2012. Legitimizing research, technology and innovation policies for transformative change: Combining insights from innovation systems and multi-level perspective in a comprehensive ‘failures’ framework. Research Policy, 41(6), pp. 1037-1047.
Winter, S.G. 2003. Understanding dynamic capabilities. Strategic Management Journal, 24(10), pp. 991-995.
Woolthuis, R.K., Lankhuizen, M. & Gilsing, V. 2005. A system failure framework for innovation policy design. Technovation, 25(6), pp. 609-619.
Yang, C.-H., Huang, C.-H. & Hou, T.C.-T. 2012. Tax incentives and R&D activity: Firm-level evidence from Taiwan. Research Policy, 41(9), pp. 1578-1588.
Zaboli, P. et al. 2016. Pharmaceutical laws and regulations in Iran: An overview. Journal of Research in Pharmacy Practice, 5(3), pp. 155.
Zahra, S.A. & George, G. 2002. Absorptive capacity: A review, reconceptualization, and extension. Academy of Management Review, 27(2), pp. 185-203.
Zahra, S.A., Sapienza, H.J. & Davidsson, P. 2006. Entrepreneurship and Dynamic Capabilities: A Review, Model and Research Agenda. Journal of Management Studies, 43(4), pp. 917-955.
Zollo, M. & Winter, S.G. 2002. Deliberate learning and the evolution of dynamic capabilities. Organization Science, 13(3), pp.339-351.
آذر، عادل و حسن زاده کریم آبادی، حمید رضا،1381، نگاشت مفهومی و کارکردهای مدیریتی آن چشم انداز مدیریت بازرگانی، تابستان و پاییز، شماره 3 و 4، صص. 77-104.
دانائی‌فرد حسن،1386. پارادایم‌های رقیب در علم سازمان و مـدیـریـت: رویـکـرد تـطبـیقـی به هستـی‌شنـاسی، شنـاخت‌شنـاسی و روش‌شناسی. راهبردهای بازرگانی-دانشور رفتار سابق؛ ۱ (۲۶)،صص. ۸۹-۱۰۴
رمضانی، ابوالفضل و میرزامحمدی، علی،1392. تحلیل شبکه‌های اجتماعی. ایران: تهران: انتشارات جامعه شناسان.
سازمان غذا و دارو،1394.آیین‌نامه‌های و مقررات.:
سلطان‌زاده، جواد، الیاسی، مهدی، بامداد صوفی، جهانیار و کزازی، ابوالفضل،1396. «شناسایی خردبنیان‌های توانمندی نوآوری شرکت‌های تولید داروی کشور: مطالعه چند موردی». فصلنامه علمی-پژوهشی بهبود مدیریت. سال یازدهم، شمار 1، پیاپی 35،صص. 206-163.
صفری، حسین، حشمتی پور، فاطمه، مهرابی، علی و نصابی، وحیدرضا،1391. مدلسازی عوامل مؤثر بر به‌اشتراک‌گذاری اطلاعات در زنجیره تأمین شرکت ایران خودرو خراسان با استفاده از روش ترکیبی نگاشت علّی و شبکه‌های بیزین. فصلنامه علمی-پژوهشی مدیریت فناوری اطلاعات، 4(10)، صص. 65-92.
صارمی، محمود، حسینی، سید محمود، محقر، علی و حیدری، علی، 1388. مدلسازی کیفی مزیت رقابتی در صنایع مبتنی بر فن‌آوری‌های پیشرفته. نشریه مدیریت صنعتی، 1(3)، صص. 53-68.
ضرغامی فرد، مژگان و آذر، عادل،1394. تحلیلی بر شیوه نگاشت شناختی در ساختار بندی داده‌های کیفی مطالعات سازمانی. مطالعات رفتار سازمانی، 3(1 ، 2 (پیاپی 8 و 9))، صص. 185-159.
کارگر شهامت بهمن، تقوا محمدرضا، طباطبائیان سید حبیب اله، صالحی صدقیانی جمشید، الزامات شکل گیری شبکه نوآوری تحلیلی از قاعده بنگاه‌داری در بخش دارویی ایران، بهبود مدیریت، سال دهم، شماره 34، صص. 94-49.
مدنی، حسام‌الدین، شاه‌حسینی، محمد حسن و خمسه، عباس،1390. تأثیر طرح ژنریک بر توسعه توانمندی‌های فناوری. مجله پژوهشی حکیم، (1) 14، صص. 31-23.
)